Global Credit Crisis Said To Open Doors For Malaysian Biotechs
This article was originally published in PharmAsia News
The current worldwide economic crisis puts Malaysian startup biotechnology companies in a good position to seek mergers and acquisitions to expand their business abroad. CEO Datuk Iskandar Mizal Mahmood of Malaysian Biotechnology said Malaysia's organization of biotechs, BioNexus, can help raise funds to buy foreign biotechs. They would be firms facing problems with obtaining credit, particularly those in the United States and Europe. He said many of those foreign companies already are seeking collaborations. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.